Peer to Peer Webinars

Discover how LYMPHOSEEK® can help deliver accuracy, precision, and efficiency in lymphatic mapping and sentinel lymph node biopsy procedures.

Discussions led by Surgeons & Nuclear Medicine Professionals

 

 

Advances in Lymphatic Mapping and Sentinel Lymph Node Biopsy in Squamous Cell Carcinoma of the Oral Cavity Cancer Care

Wednesday, April 9th, 3-4 pm ET
Presented by: Stephen Y Lai, MD, PhD, FACS

Register

 

Advances in Lymphatic Mapping and Sentinel Lymph Node Biopsy in Breast Cancer Care

Tuesday, May 13th, 3-4pm ET
Presented by: Dr. Laura Lawson and Dr. Linda Han

Register 

 

Delivering Efficiency in Sentinel Lymph Node Biopsy (1-hour CE credit)

Thursday, June 26th, 12-1pm ET
Presented by: Vincent Reid, MD

Register 

 

Form title

About the speaker

Dr. Linda Han, MD, FACS, PPG
Breast Surgical Oncologist, West Cancer Center & Research Institute, Memphis, TN

About the speaker

Dr. Laura Lawson, MD
Medical Director
Ascension St. Thomas Breast Cancer Program
Assistant Professor of Clinical Surgery
Vanderbilt University

About the speaker

Dr. Stephen Y. Lai, MD, PhD, FACS
Professor, Head and Neck Surgery
The University of Texas MD Anderson Cancer Center

About the speaker

Dr. Vincent Reid, MD
Chairman, Department of Surgery
Mercy Medical Center

Indications and Usage

LYMPHOSEEK® (technetium Tc 99m tilmanocept) injection is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

  • Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adult and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management.
  • Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

 

Important Safety Information

Warnings and Precautions

  • LYMPHOSEEK® may pose a risk of hypersensitivity reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs). No serious hypersensitivity reactions were reported in clinical trials with LYMPHOSEEK®.
  • Before administering LYMPHOSEEK®, ask patients about prior hypersensitivity reactions to drugs, especially to dextran and modified forms of dextran. Have resuscitation equipment and trained personnel immediately available at the time of LYMPHOSEEK® administration.
  • LYMPHOSEEK® is a radioactive drug and should be handled by or under the control of qualified and licensed physicians with appropriate safety measures to help decrease radiation exposure.
  • Any radiation-emitting product may increase the risk for cancer, especially in pediatric patients. Adhere to the dose recommendations and ensure safe handling to decrease the risk for excessive radiation exposure to either patients or health care workers.

Adverse Reactions

  • The most common adverse reactions are injection site irritation and injection site pain (<1%).
  • There were no serious adverse reactions seen in clinical trials. 

Use in Specific Populations

  • No data are available on LYMPHOSEEK® use in pregnant women. If considering LYMPHOSEEK® administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • No data are available regarding the presence of technetium Tc 99m tilmanocept in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. The benefits of breastfeeding should be considered along with the mother’s clinical need for LYMPHOSEEK® and any potential adverse effects on the breastfed child. If considering LYMPHOSEEK® administration to a lactating woman, advise to pump and discard breast milk for 24 hours after injection to decrease radiation exposure to the breastfed child.
  • The safety and effectiveness of LYMPHOSEEK® have been established in pediatric patients 1 month of age and older.
  • In clinical studies, no differences in safety or efficacy have been identified between elderly patients (65 to 90 years of age), younger adult patients (18 to 65 years of age), and pediatric patients (1 month of age and older).

Please see full Prescribing Information.

To report suspected adverse reactions, contact Cardinal Health at 1.800.618.2768 or FDA at  1.800.FDA.1088 or www.fda.gov/medwatch.

The information on this web site is intended for use only by healthcare professionals in the United States.